TY - JOUR
T1 - Assessment of endpoints for clinical trials for localized prostate cancer
AU - Schellhammer, Paul
AU - Cockett, Abraham
AU - Boccon-Gibod, Laurent
AU - Gospodarowicz, Mary
AU - Krongrad, Arnon
AU - Thompson, Ian Murchie
AU - Scardino, Peter
AU - Soloway, Mark
AU - Adolfsson, Jan
N1 - Funding Information:
APPENDIX: EXECUTIVE COMMITTEE MEMBERS William Fair, MD, Memorial Sloan-Kettering Cancer Center, New York, New York, Cochair; Marc B. Garnick, MD, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts, Cochair; Jean Fourcroy MD, PhD, US Food and Drug Administration, Bethesda, Maryland; Richard S. Kaplan, MD, National Institutes of Health, Bethesda, Maryland; Colin Begg, MD. Memorial Sloan-Ketterine Cancer Center. New York, New York; Nicholas Bruchovsk;, MD, NCIC, Vancouver, British Columbia, Canada; Hank Porterfield, US TOO, Hinsdale, Illinois; Wim PJ Witjes, MD, University Hospital, Nijmegen, Netherlands; M.P. Demos, MD, JD, American Institute of Medical Law, Coral Gables, Florida.
PY - 1997/4
Y1 - 1997/4
N2 - Objectives. The AUA Practice Guidelines Panel convened to address the issue of appropriate endpoints for assessment of treatment modalities for localized carcinoma of the prostate. Methods. A review of the literature and the design of existing clinical trials produced a consensus, which was presented to and critiqued by the members of the general conference. Results. The pitfalls associated with identification of local failure endpoints were discussed, and the more accurate endpoints of freedom from metastatic progression and overall survival were recognized. The strict definition that must be fulfilled for intermediate endpoints to become surrogates for metastasis free and/or survival endpoints was stressed. For more efficient and rapid conduct of future clinical trials, the urgent need to validate such surrogate endpoints by evaluation in randomized control trials is obvious. PSA, while an indicator of disease activity and a critical marker for estimating disease progression or regression in response to therapy, is not a surrogate for metastasis free or overall survival. Conclusion. Until surrogate endpoints are validated, the committee has evaluated the endpoints in current use, reviewed their limitations, and stressed the importance of quality-of-life assessment together with the traditional endpoint assessment.
AB - Objectives. The AUA Practice Guidelines Panel convened to address the issue of appropriate endpoints for assessment of treatment modalities for localized carcinoma of the prostate. Methods. A review of the literature and the design of existing clinical trials produced a consensus, which was presented to and critiqued by the members of the general conference. Results. The pitfalls associated with identification of local failure endpoints were discussed, and the more accurate endpoints of freedom from metastatic progression and overall survival were recognized. The strict definition that must be fulfilled for intermediate endpoints to become surrogates for metastasis free and/or survival endpoints was stressed. For more efficient and rapid conduct of future clinical trials, the urgent need to validate such surrogate endpoints by evaluation in randomized control trials is obvious. PSA, while an indicator of disease activity and a critical marker for estimating disease progression or regression in response to therapy, is not a surrogate for metastasis free or overall survival. Conclusion. Until surrogate endpoints are validated, the committee has evaluated the endpoints in current use, reviewed their limitations, and stressed the importance of quality-of-life assessment together with the traditional endpoint assessment.
UR - http://www.scopus.com/inward/record.url?scp=0030905231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030905231&partnerID=8YFLogxK
U2 - 10.1016/S0090-4295(99)80321-5
DO - 10.1016/S0090-4295(99)80321-5
M3 - Article
C2 - 9111612
AN - SCOPUS:0030905231
VL - 49
SP - 27
EP - 38
JO - Urology
JF - Urology
SN - 0090-4295
IS - 4 SUPPL.
ER -